AKTUALITĀTES
   
62941

Monoklonālās HIV antivielas samazināja vīrusu slodzi
Apskatīt komentārus (0)


27.12.2015


Jaunās zāles VRC01 izstrādāja ASV Alerģijas un infekcijas slimību nacionālā institūta (U.S. National Institute of Allergy and Infectious Diseases) speciālisti Antonija Foci (Anthony Fauci) vadībā.
Pētījumā, ko veica amerikāņu zinātnieki, piedalījās 23 cilvēki ar HIV, no kuriem 15 lietoja antiretrovīrusu terapiju, bet astoņi – neizmantoja šādu terapiju.
Zāles labi panesa un tās neizraisīja nopietnas blaknes. Turklāt antivielas bija stabilas un asinīs cirkulēja vairākas nedēļas. Cilvēkiem, kuri lietoja antiretrovīrusu preparātus, veica divas antivielu injekcijas ar intervālu 28 dienas, bet tiem, kuriem nebija šādas terapijas, zāles injicēja vienreiz.
Zinātnieki pierādīja, ka vienreizēja VRC01 injicēšana ļāva samazināt vīrusa līmeni asinīs tiem pacientiem, kuri  neuzņēma antiretrovīrusu preparātus.  Sešiem no astoņiem pacientiem vīrusu slodze samazinājās desmitkārt. Jaunā preparāta efektivitātes un nekaitīguma pārbaude tiks turpināta arī nākamajā gadā.
*******************************
MedicalExpress | «HIV antibody infusion safely suppresses virus in infected people» | http://medicalxpress.com/news/2015-12-hiv-antibody-infusion-safely-suppresses.html |
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today. The researchers also found that giving HIV-infected people VRC01 antibodies by infusing them into a vein or under the skin is safe and well tolerated, and the antibodies remain in the blood for an extended period.
The Phase 1 clinical trial conducted by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) involved 23 HIV-infected people, 15 of whom were taking ART and eight of whom were not. The individuals on ART received two infusions of VRC01 28 days apart, and those not on ART received one antibody infusion. The investigators assessed whether the antibody infusions were safe and whether they reduced the amount of HIV in blood plasma (the viral load) or within blood cells.
The researchers found that while antibody infusions did not reduce the amount of HIV in blood cells, they reduced plasma viral load more than 10-fold in six of the eight people who were not on ART. In the two people in this group who began the study with the lowest viral loads, the antibody suppressed HIV to extremely low levels for approximately 3 weeks—as long as VRC01 was present at therapeutic concentrations. In the other four people whose HIV levels declined, their viral load fell substantially but did not reach undetectable levels. In the two people not on ART whose viral loads remained steady despite the antibody infusion, it was subsequently found that the predominant HIV strain in their bodies had been resistant to VRC01 at the outset. The antibody also did not appear to have any effect in people taking ART, whose virus was already suppressed.
Several ongoing NIAID clinical studies will further elucidate the potential role of HIV antibodies in treating or preventing HIV infection.

 


 
      Atpakaļ

atstāj tukšu: atstāj tukšu:
vārds:




Ievadiet drošības kodu:

Visual CAPTCHA



Gaismas iela 19 k-8, Ķekava, Ķekavas pagasts, Ķekavas novads, LV-2123, Latvija

Logo +371 26062077
Logo apvieniba@apvienibahiv.lv